The real cost of capital for innovation companies

When founders think about the cost of funding, the conversation often starts with interest rates, repayment schedules or valuations. Those numbers matter, but they do not tell the full story.

For innovation companies, capital decisions shape more than the balance sheet. They can influence how quickly a business can hire, how much R&D it can complete, when it can commercialize, and how much ownership founders retain as the company grows.

That is why the real cost of capital is not simply what funding costs today. It is what that funding decision means for the business over time.

This blog focuses on the real cost of two common sources of growth capital: debt financing and equity financing. While grants, bootstrapping and revenue all play important roles in many funding strategies, the purpose of this blog is to compare the trade-offs between borrowing capital and giving up ownership in return for venture capital (VC).

Understanding the real cost of funding

Debt and equity financing are often compared too simply.

Debt financing has a visible cost. Interest rates, fees and repayment terms are usually clear from the outset, which makes the cost easy to identify and scrutinize.

Equity financing can feel less expensive in the short term because there are no scheduled repayments. But equity has a different kind of cost. When founders exchange ownership for capital, they are also giving up a share of future value if the company grows.

Neither option is inherently better. And many innovation companies use both at different stages of their business journey. The important question is whether the type of capital matches the company’s current needs, timing and long-term goals.

Cost considerations for debt financing

Debt financing involves borrowing money that is repaid over time, usually with interest. For innovation companies, this may include bank lending, venture debt, equipment financing, or SR&ED financing.

If you’re claiming Scientific Research and Experimental Development credits, SR&ED financing is a specific form of debt financing that is tied to your expected SR&ED refund. Rather than waiting until the claim is processed, a business can access part of that expected refund earlier and repay the advance when the refund arrives.

The advantage of debt financing is that the cost is usually defined upfront. A business can assess the interest rate, fees, repayment terms, and security requirements before deciding whether the funding makes sense.

That visibility can make debt feel expensive, because the cost is clear. On the plus side, it also makes debt easier to model in your financial planning.

What is less obvious is the value of time. Debt financing is often easier, quicker, and more predictable than other sources of capital and can help a company keep R&D, product development, and commercialization moving forward.

When weighing up the cost of capital, R&D-intensive companies need to consider not only what the financing costs up front, but what earlier access to capital may help the business achieve. If delayed funding slows hiring, product development, or commercialization, those delays may not appear in a repayment schedule, but they can still affect growth.

Cost considerations for equity financing

Equity financing works differently to debt financing. Instead of repaying the capital, companies exchange ownership in the business for investment.

Equity financing can be powerful. It can help companies scale, enter new markets, hire senior talent, and fund ambitious growth plans. It is often essential for businesses pursuing large opportunities or long development timelines.

While equity financing doesn’t require monthly repayments, it still has a cost.

Every percentage of ownership given away today represents a share of the company’s future value. If the business grows significantly, the long-term cost of that dilution can be much higher than it appeared at the time of the raise. That does not mean equity is the wrong choice. It means equity should be used deliberately, particularly when non-dilutive options may help a company reach a stronger position before raising.

Comparing the cost of debt and equity in practice

Consider a fictional, early stage Canadian software company called MapleGrid Systems.

MapleGrid is developing a software platform for energy infrastructure operators and expects to receive a $400,000 SR&ED refund after filing its next claim. The company is also preparing for a major product release and wants to keep its development team focused on testing, integration and customer implementation.

MapleGrid needs additional capital to keep development moving and reach its next commercial milestone. The company is considering an equity raise in the future, but its founders believe the business will be in a stronger position once the product release is complete and early customer implementation is underway.

At this point, MapleGrid has three options:

1. Slow spending while waiting for its SR&ED refund, which may delay development, hiring or commercialization.
2. Raise equity earlier than planned, before reaching the milestone that could support a stronger valuation.
3. Use an Easly Advance to access part of its expected SR&ED refund earlier, continue investing in eligible R&D, and build towards a potential future raise from a stronger position.

Option 1: Wait for the SR&ED refund

MapleGrid could slow spending and wait for its $400,000 SR&ED refund to arrive.

On paper, this may look like the lowest-cost option because the company avoids both financing costs and dilution. But waiting can create its own cost.

If MapleGrid slows development, delays hiring, or pushes back customer implementation, it may lose momentum at the exact point when speed matters. Competitors may reach the market sooner, early adopters may lose interest, or the company may miss the chance to prove traction before a planned raise.

In this scenario, the cost is not shown as an interest rate or ownership percentage. It shows up as delayed progress, reduced leverage, and a weaker position when the company eventually approaches investors.

Option 2: Raise equity earlier than planned

MapleGrid could raise equity now, before completing its product release and early customer implementation.

The company has a starting (pre-money) valuation of $2 million, raises $300,000 and pays $9,000 in fees in return for 13% of the business.

At the time, that may feel like a reasonable trade-off for the capital needed to keep development moving. But if MapleGrid achieves its ambitious growth plans and exits for $50 million, that 13% would represent $6.5 million in value.

That does not mean equity is the wrong choice. VC funding can provide significant capital, strategic advice, and valuable networks. But it does come with the cost of dilution, reduced ownership, pressure to deliver investor returns and, more often than not, less control over future decisions.

Option 3: Use SR&ED financing to build towards the raise

Alternatively, MapleGrid could use an Easly Advance to access part of its expected SR&ED refund earlier. With an expected refund of $400,000, MapleGrid is able to access 75% of the expected refund, or $300,000, through SR&ED financing.

That $300,000 could help MapleGrid continue eligible R&D, complete testing, support customer implementation, or make a key technical hire while it waits for its refund.

Maplegrid takes the $300,000 SR&ED financing loan over six months with an approximate annual interest rate of 15% and pays $49,000 in fees and interest. The advance has a financing cost, so it should still be assessed carefully. But MapleGrid retains 100% ownership while using capital already tied to its expected SR&ED refund. Presuming the same trajectory as the equity example, the owners retain 100% of ownership and retain all proceeds from the $50 million exit.

In this example, the real comparison is not simply between debt and equity. It is between waiting, raising before the business has built more value, or using SR&ED financing to keep moving while preserving equity. That is why timing matters so much to the cost calculation.

How timing impacts the calculation

How and when a company can access capital can make a big difference to speed and outcomes, both for research milestones and commercialization.

Grant funding can be valuable, but applications may be competitive, time-consuming and tied to specific eligibility criteria or reporting requirements. VC financing can provide significant funding and strategic support, but the process can take months – during which time a founder’s capacity to attend to other parts of the business is limited – and may depend on investor appetite, market conditions, and valuation. Traditional debt may be difficult to access without assets, revenue history, or personal guarantees.

For innovation companies, those timing differences matter. A funding option that looks more expensive on paper may be valuable if it helps the business reach a technical, commercial or regulatory milestone. A funding option that looks cheaper in the short term may become expensive if it requires the company to give up ownership before its value has increased.

This is where opportunity cost becomes important. If a business delays hiring, commercialization or market entry because capital is unavailable, those delays can carry significant cost. The challenge is to compare that true cost against the cost of financing, rather than looking at numbers in isolation. For some companies, paying for access to capital sooner may be more strategic than choosing the option that appears cheapest upfront.

A more strategic way to fund R&D

Debt and equity are often framed as competing options but, in practice, they can work together.

Equity may be the right tool for major expansion, market entry, or long-term growth. Debt may be useful when a company wants defined costs, a shorter funding period, or a way to preserve ownership. SR&ED financing can play a more specific role by helping businesses access capital already tied to expected tax credits.

For many Canadian innovation companies, the strongest funding strategy is not about choosing one source of capital. It is about using the right type of funding at the right time, so each decision supports the next stage of growth.

The real cost of capital is not just the interest rate, valuation, or repayment term. It is the effect that funding decision has on ownership, timing, and growth.